Heart failure associated with anemia: Use of intravenous iron compared to placebo

• Autor(a) principal: Sousa, Caroline Melo de
• Data de Publicação: 2021
• Outros Autores: Araújo, Heloisa da Silva, Frutuoso, Lais Pinheiro, Silveira, Maria Cândida Alencar da, Linhares, Germana Lacerda, Sousa, Milena Nunes Alves de, Farias, Tiago Bruno Carneiro de
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/17732
• topic: Deficiencia de hierro; Anemia por deficiencia de hierro; Insuficiencia cardíaca.; Deficiencia de hierro; Anemia por deficiencia de hierro; Insuficiencia cardíaca.; Deficiência de ferro; Deficiência de ferro;Anemia Ferropriva; Insuficiência Cardíaca.; Anemia Ferropriva; Insuficiência Cardíaca.; Iron deficiency; Iron deficiency anemia; Cardiac insufficiency.; Iron deficiency; Iron deficiency anemia; Cardiac insufficiency.

Heart failure (HF) is a syndrome in which the heart has its capacity to fill or eject the ventricles decreased. Iron deficiency is commonly associated with HF and has been shown to be a factor of worse prognosis. The aim of this study is to evaluate patients affected by heart failure for intravenous iron supplementation compared to non-supplementation (or placebo). In this systematic review, a bibliographic search was conducted in the electronic databases Virtual Health Library, Capes Journal Portal and SciSearch. The Health Sciences Descriptors (DeCS) Heart Failure, Iron deficiency anemia and Iron Deficiency were used. The GRADE System was used to evaluate the quality of evidence of the articles analyzed, and 11 Randomized Clinical Studies covering 5 nationalities were included. Symptomatic patients diagnosed with HF associated with Ironpriva Anemia showed improvements in primary outcomes on the global self-assessment scale and in the New York Heart Association (NYHA) functional class when receiving intravenous iron replacement when compared to those receiving placebo. In addition, there were no significant improvements in patients regarding oral iron treatment. Thus, it is concluded that anemia has important repercussions for patients affected by HF, being related to a worse prognosis. Therefore, intravenous iron supplementation is necessary to improve symptoms and quality of life, and should be monitored by specialists due to the possible adverse reactions that may appear.